Money Matters

Money Matters

Q1 Results

Biocon sales increase 21 percent

Biocon’s consolidated sales at Rs 212 crore increased 22 percent over Q1 FY06 (Rs 174 crore). The EBITDA margins were at 26 percent, down four percent from Q1 FY06 (30 percent). This can be attributed to an adverse impact of Rs 3 crore due to foreign exchange movement, lower statin prices and a 50 percent increase in R&D spend over Q1 FY06.

Orchid net PAT up by 99 percent

Orchid Chemicals & Pharmaceuticals achieved a turnover and operating income of Rs 201.71 crore for the quarter ended June 30, 2006 in comparison to Rs 170.26 crore registered during the corresponding first quarter of the last fiscal. Net profit after tax increased by 99 percent and stood at Rs 14.59 crore as compared to Rs 7.33 crore of Q1 last fiscal. On a consolidated basis, Orchid registered a turnover and operating income of Rs 212.65 crore for the quarter ended June 30, 2006 in comparison to Rs 187.82 crore registered during the corresponding first quarter of last fiscal.

Granules net sales boosts by 36.61 percent

Granules India has posted 36.61 percent rise in net sales at Rs 47.74 crore for the fourth quarter ended June 2006 compared to Rs 34.95 crore in the corresponding quarter last year. Net sales during the quarter grew by 25.74 percent at Rs 2.43 crore compared to Rs 1.94 crore in the corresponding quarter ended June 2006. Meanwhile, the company posted a 42.83 percent rise in net profit at Rs 9.52 crore for the year ended June 2006 compared to Rs 6.66 crore in the corresponding period last year.

Strides revenue up 28 percent

Strides Arcolabs’ consolidated sales for the second quarter ended June 30, 2006 increased to Rs 1,682 million by 28 percent over the corresponding year Q2 FY05 at Rs 1311 million. The company’s EBITDA margins at 13.21 percent were significantly lower by 10 percent from Q1 FY06.

DRL’s revenues drive R&D

Dr Reddy’s unaudited financial results for the quarter ended June 30, 2006 demonstrate a net income of Rs 1,398 million. The total revenues stand at Rs 14 billion as against Rs 5.6 billion in Q1 FY06. Gross profits increase to Rs 6.1 billion in Q1 FY07 from Rs 2.9 billion in Q1 FY06. The company’s R&D investments have increased by three percent to Rs 533 million as against Rs 515 million in Q1 FY06.

Glenmark’s US business earns Rs 230.76 mn

Glenmark Pharmaceuticals posted consolidated revenues of Rs 1915.53 million for the first quarter of the financial year 2006-07 ended June 30, 2006. It registered a growth of 21.47 percent compared to the corresponding period of the previous year. In the period under review, Glenmark’s US business earned revenues of Rs 230.76 million, whereas revenues from the Indian formulations segment registered a marginal decline of 1.31 percent at Rs 861.38 million.

GSK driven by sales growth of 13 percent

GSK registered a sales growth of 13 percent during the half year ended June 30, 2006. Profit before tax and exceptional items grew by 20 percent for the first half of 2006, with continued emphasis on product-mix improvement and control over expenses.

Suven’s revenues rise by 60 percent

Suven Life Sciences’ revenues show an increase by 60 percent to Rs 2,562.50 lakh for the first quarter ending June 2006 as compared to Rs 1,594.26 lakh for the corresponding quarter of the previous year. Profit after tax is up by 51 percent from Rs 137.67 lakh to Rs 208.32 lakh. The company’s exports have gone up by 92 percent from Rs 1081 lakh to Rs 2,084 lakh. Suven’s major thrust on R&D in drug discovery continues with an expenditure of Rs 399 lakh recording about 16 percent of total revenue for the quarter.

Zydus Cadilla net profit grows by 71 percent

For the first quarter ended June 30, 2006, Zydus Cadila reported total income of Rs 451 crore, up 21 percent from Rs 373 crore in the corresponding quarter of the previous year on a consolidated basis. The net profit was up by 71 percent to Rs 58 crore from Rs 34 crore in the first quarter of 2005-06. Income growth was mainly driven by an overall growth of 131 percent in formulation exports.

Ajanta Pharma achieves 30 percent growth

Ajanta has continued its growth with a 30 percent increase in its sales for the quarter ended June 30, 2006 with a sales achievement of Rs 46.02 crore for the quarter, against Rs 35.30 crore for corresponding period in the previous year. The company’s profit after tax stood at Rs 1.29 crore, as compared to Rs 0.79 crore in Q1 FY05 demonstrating a growth of 65 percent.

Sun Pharma’s total income up 49 percent

Sun Pharma has shown a 49 percent increase in the total income at Rs 4,751 million as compared to last year’s Rs 3,178 million. The net profit stands at Rs 1,429 million, which is up by 38 percent vis-à-vis Rs 1,034 million in Q4 FY05.

Shasun’s net profit up 45 percent

Shasun Chemicals and Drugs posted a 44.84 percent rise in net profit at Rs 6.17 crore for the first quarter ended June 30, 2006 as compared to Rs 4.26 crore for the quarter ended June 30, 2005. Revenues during the quarter grew 28.73 percent at Rs 99.46 crore as compared to Rs 77.26 crore in Q1 FY06. During the quarter, the company witnessed significant improvement in revenues from CRAMS. Gross profit during the quarter grew by 20.65 percent at Rs 14.90 crore, as compared to Rs 12.35 crore in Q1 FY06.